Comparison of different transplantation routes and timing for stem cell therapy in stroke
7 affiliations
- 1Shanghai Institute of Aviation Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 2Department of Neurosurgery, Huixian People’s Hospital, Huixian, Xinxiang, China
- 3Department of Emergency Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 4Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
- 5Department of Neurosurgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 6Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
- 7Department of Neurosurgery, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Abstract
Background: Stem cell transplantation holds therapeutic promise for stroke, yet its clinical translation is hindered by unresolved challenges in administration routes, timing, and poor cell engraftment and survival.
Methods: This is a narrative (non-systematic) review. Registered clinical studies were identified in ClinicalTrials.gov, the European Union Clinical Trials Register and the Chinese Clinical Trial Registry, and were supplemented by targeted PubMed searches for the preclinical and mechanistic literature. Records were eligible if they evaluated stem cell transplantation for ischemic or hemorrhagic stroke and reported the delivery route and/or the transplantation time window; records reporting neither were excluded. Because direct head-to-head clinical comparisons of routes and time windows are scarce, registry data and selected preclinical studies were synthesised descriptively rather than pooled, and no meta-analysis was performed.
Results: Each administration route presents a distinct profile. Intravenous injection is minimally invasive and simple but limited by pulmonary sequestration, low cerebral engraftment, and high cell dose requirements. Intra-arterial infusion offers improved targeting but shares similar limitations. Intrathecal delivery allows direct central nervous system access with concentrated doses but carries risks of cerebrospinal fluid leakage and an inflammatory microenvironment. Intracerebral implantation ensures high local engraftment and long-term survival with minimal cell numbers but is invasive and poses risks of hemorrhage and further tissue injury. Intranasal administration is non-invasive with a wide therapeutic window yet exhibits extremely low delivery efficiency. Regarding timing, intravenous and intra-arterial routes are primary in the acute phase; in the subacute phase these routes remain common, alongside intrathecal administration; for chronic stroke, intracerebral and intrathecal transplantation are the predominant strategies in clinical trials.
Conclusion: This review synthesizes two decades of progress and persisting challenges in stem cell therapy for stroke, focusing on delivery strategies and timing. Successful clinical translation will require further large-scale, multicenter prospective studies to optimize these critical parameters.
Related
- Beginning Kidney Replacement Therapy Before or After Liver Transplantation: Does the Timing of Dialysis Matter? A Cohort Study.
- Kidney transplantation in multiple myeloma: patient selection, timing, and post-transplant challenges in the modern therapeutic era
- Narratives about Breaking the Cycle of Intergenerational Violence in Families: Different Routes, Same Goal
- Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
- Clinical treatment of tubal pregnancy with methotrexate: a comparison of intramuscular and intravenous routes in a randomized clinical trial
BibTeX
@article{meng2026comparison,
title = {{Comparison of different transplantation routes and timing for stem cell therapy in stroke}},
author = {Qingdong Meng and Hao Deng and Ziqian Zhang and Yongxu Wei and Mingjian Liu and Bin Chen and Yijun Cheng and Hanbing Shang},
journal = {Annals of Medicine},
year = {2026},
month = nov,
doi = {10.1080/07853890.2026.2753828},
url = {https://doi.org/10.1080/07853890.2026.2753828},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparison of different transplantation routes and timing for stem cell therapy in stroke
AU - Qingdong Meng
AU - Hao Deng
AU - Ziqian Zhang
AU - Yongxu Wei
AU - Mingjian Liu
AU - Bin Chen
AU - Yijun Cheng
AU - Hanbing Shang
PY - 2026
DA - 2026/11/03
JO - Annals of Medicine
DO - 10.1080/07853890.2026.2753828
UR - https://doi.org/10.1080/07853890.2026.2753828
AB - Background: Stem cell transplantation holds therapeutic promise for stroke, yet its clinical translation is hindered by unresolved challenges in administration routes, timing, and poor cell engraftment and survival. Methods: This is a narrative (non-systematic) review. Registered clinical studies were identified in ClinicalTrials.gov, the European Union Clinical Trials Register and the Chinese Clinical Trial Registry, and were supplemented by targeted PubMed searches for the preclinical and mechanistic literature. Records were eligible if they evaluated stem cell transplantation for ischemic or hemorrhagic stroke and reported the delivery route and/or the transplantation time window; records reporting neither were excluded. Because direct head-to-head clinical comparisons of routes and time windows are scarce, registry data and selected preclinical studies were synthesised descriptively rather than pooled, and no meta-analysis was performed. Results: Each administration route presents a distinct profile. Intravenous injection is minimally invasive and simple but limited by pulmonary sequestration, low cerebral engraftment, and high cell dose requirements. Intra-arterial infusion offers improved targeting but shares similar limitations. Intrathecal delivery allows direct central nervous system access with concentrated doses but carries risks of cerebrospinal fluid leakage and an inflammatory microenvironment. Intracerebral implantation ensures high local engraftment and long-term survival with minimal cell numbers but is invasive and poses risks of hemorrhage and further tissue injury. Intranasal administration is non-invasive with a wide therapeutic window yet exhibits extremely low delivery efficiency. Regarding timing, intravenous and intra-arterial routes are primary in the acute phase; in the subacute phase these routes remain common, alongside intrathecal administration; for chronic stroke, intracerebral and intrathecal transplantation are the predominant strategies in clinical trials. Conclusion: This review synthesizes two decades of progress and persisting challenges in stem cell therapy for stroke, focusing on delivery strategies and timing. Successful clinical translation will require further large-scale, multicenter prospective studies to optimize these critical parameters.
SN - 0785-3890
SN - 1365-2060
ER -